This article is more than 5 years old. Information may no longer be current.

FDA grants tentative approval for generic Prolensa

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted tentative approval to Perrigo Company plc for its generic version of Prolensa, according to a company press release.

Prolensa (bromfenac ophthalmic solution 0.07%, Bausch + Lomb), a nonsteroidal anti-inflammatory drug for treating inflammation and ocular pain in cataract surgery patients, had branded market sales of $113 million in the past 12 months, according to the Perrigo press release.

The tentative approval demonstrates the company’s “continued dedication” to delivering “quality affordable health care products,” the company’s executive vice president and president of Rx Pharmaceuticals teams John Wesolowski said in the release.